Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. Among authors: orloff m. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. Among authors: orloff m. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Free article. Clinical Trial.
Review of bi-specific therapies in uveal melanoma.
Orloff M, Seedor R, Sato T. Orloff M, et al. Cancer Gene Ther. 2022 Dec;29(12):1814-1818. doi: 10.1038/s41417-022-00442-9. Epub 2022 Mar 2. Cancer Gene Ther. 2022. PMID: 35236927 Review.
Treatment of Metastatic Melanoma in the Elderly.
Seedor RS, Orloff M. Seedor RS, et al. Among authors: orloff m. Curr Oncol Rep. 2022 Jul;24(7):825-833. doi: 10.1007/s11912-022-01257-5. Epub 2022 Mar 22. Curr Oncol Rep. 2022. PMID: 35316844 Review.
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Hamid O, et al. Among authors: orloff m. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. J Immunother Cancer. 2023. PMID: 37286303 Free PMC article. Clinical Trial.
Melanoma Immunotherapy in the Elderly.
Orloff M. Orloff M. Curr Oncol Rep. 2018 Mar 2;20(2):20. doi: 10.1007/s11912-018-0656-3. Curr Oncol Rep. 2018. PMID: 29500787 Review.
439 results